检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:王美惠[1] 毕徐堃 傅国胜[1] WANG Mei-hui;BI Xu-kun;FU Guo-sheng(Department of Cardiovascular Diseases,Sir Run Run Shaw Hospital,College of Medicine,Zhejiang University,Hangzhou 310016,China)
机构地区:[1]浙江大学医学院附属邵逸夫医院心内科
出 处:《基础医学与临床》2019年第6期769-775,共7页Basic and Clinical Medicine
基 金:国家自然科学基金(81570246);浙江省卫计委省部共建项目(201477370)
摘 要:目的观察瑞舒伐他汀对脂多糖(LPS)诱导的人外周血晚期内皮祖细胞(LOCs)损伤的影响,探讨其可能的机制。方法密度梯度离心法获取人外周血单个核细胞并培养获得LOCs。实验分为对照组、LPS诱导组以及不同浓度瑞舒伐他汀和LPS共处理组。用CCK-8法检测细胞活力;比色法检测细胞培养上清液中丙二醛(MDA)的含量及乳酸脱氢酶(LDH)、超氧化物歧化酶(SOD)的活性;流式细胞术检测细胞内活性氧(ROS)水平;ELISA试剂盒检测细胞培养液中IL-6、IL-8水平;Westernblot检测Toll样受体4(TLR4)蛋白表达;转录因子活性检测试剂盒检测NFκBp65转录活性。结果瑞舒伐他汀能有效抑制LPS作用下LOCs活力损失(P<0.05),降低细胞培养液中MDA含量及LDH活性(P<0.05),增加SOD活性(P<0.05),抑制LPS引起的ROS水平增高(P<0.01),降低炎性因子IL-6、IL-8的表达水平(P<0.01),并显著抑制LPS诱导的TLR4蛋白表达(P<0.05)和NFκBp65的转录活性(P<0.01)。结论瑞舒伐他汀能提升LPS作用下LOCs的细胞活力,减少LPS诱导的ROS生成和氧化损伤,并减少炎性因子IL-6、IL-8的表达,其抗损伤机制可能与TLR4/NFκBp65信号通路有关。Objective To investigate the effect and mechanisms of rosuvastatin in lipopolysaccharide(LPS) induced late outgrowth endothelial progenitor cells(LOCs) injury. Methods Mononuclear cells were isolated from human peripheral blood by density gradient centrifugation and cultured to obtain the LOCs. Attached cells were divided into control group, LPS treated group and rosuvastatin with different concentrations and LPS groups. CCK-8 was used to measure the cell viability. Malondialdehyde(MDA), lactate dehydrogenase(LDH) and superoxide dismutase(SOD) were examined by colorimetric assay kits. Flow cytometry was used to analyze the production of reactive oxygen species(ROS). Enzyme-linked immuno sorbent assay was utilized to detect the protein level of IL-6 and IL-8. Western blot was used to determine the TLR4 expression level and the transcription factor assay kit was used to measure the activity of NFκB p65. Results Rosuvastatin significantly inhibited the decrease of cell viability(P<0.05) induced by LPS and reduce the level of MDA(P<0.05), LDH(P<0.05), ROS(P<0.01), increasethe activity of SOD(P<0.05), decreased the expression of IL-6 and IL-8(P<0.01). Moreover, the overexpression of TLR4 and the activation of NFκB p65 induced by LPS were both inhibited by rosuvastatin(P<0.05,P<0.01). Conclusions Rosuvastatin significantly increases LOCs viability and decreases the production level of ROS, reduces the oxidative damage and inhibits IL-6 and IL-8 expression in LOCs induced by LPS. The mechanisms may be associated with TLR4/NFκB p65 signaling pathway.
分 类 号:R541.4[医药卫生—心血管疾病] R965[医药卫生—内科学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:3.16.68.255